NCT05118386 - Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

August 23, 2022

Study Completion Date

December 7, 2022

Conditions

RSV Infection

Interventions

DRUG

RSM01

"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM"

OTHER

Placebo

"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"

Trial Locations (1)

PPD Phase I Clinic - Orlando, Orlando